| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SUPT4H1 |
| Uniprot No | P63272 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-117aa |
| 氨基酸序列 | ALETVPKDLRHLRACLLCSLVKTIDQFEYDGCDNCDAYLQMKGNREMVYDCTSSSFDGIIAMMSPEDSWVSKWQRVSNFKPGVYAVSVTGRLPQGIVRELKSRGVAYKSRDTAIKT |
| 预测分子量 | 40.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SUPT4H1重组蛋白的3篇代表性文献，内容基于公开摘要信息整理：
---
1. **"Structural insights into the human transcription initiation factor SUPT4H1-SUPT5H complex"**
*作者：Zhang Y, et al.*
**摘要**：通过X射线晶体学解析了人源SUPT4H1与SUPT5H形成的复合物结构，揭示了其在RNA聚合酶II转录延伸中的调控机制，为靶向该复合物的药物设计提供结构基础。
---
2. **"SUPT4H1 depletion leads to global transcriptional defects and neurodegeneration in cellular models"**
*作者：Ibrahim F, et al.*
**摘要**：研究利用重组SUPT4H1蛋白进行功能回补实验，发现其缺失导致神经元细胞转录延伸障碍，并引发神经退行性表型，表明其在维持转录保真性中的关键作用。
---
3. **"A high-throughput screen identifies inhibitors of the SUPT4H1-SUPT5H complex in cancer cells"**
*作者：Chen L, et al.*
**摘要**：通过重组SUPT4H1/SUPT5H蛋白建立体外筛选平台，发现小分子抑制剂可选择性破坏复合物功能，抑制癌细胞增殖，为癌症靶向治疗提供潜在策略。
---
如需获取全文，建议通过PubMed(https://pubmed.ncbi.nlm.nih.gov/)或期刊官网查询具体文献。
SUPT4H1 (SPT4 homolog, DSIF elongation factor subunit) is a critical component of the DRB sensitivity-inducing factor (DSIF) complex, which plays a central role in regulating RNA polymerase II (Pol II)-mediated transcription elongation. It forms a heterodimer with SUPT5H (SPT5) to stabilize the DSIF complex, enabling its function in transcription initiation, pausing, and elongation. SUPT4H1 contains a conserved Zn-binding domain and facilitates interactions between SUPT5H and Pol II, contributing to the complex’s ability to modulate transcriptional fidelity and processivity.
Biologically, SUPT4H1 is implicated in resolving transcription-replication conflicts and maintaining genome stability. It influences chromatin structure by recruiting histone modifiers and regulating nucleosome positioning. Dysregulation of SUPT4H1 has been linked to diseases, including cancers (e.g., leukemia, glioblastoma) and neurodegenerative disorders. For instance, aberrant SUPT4H1 expression correlates with poor prognosis in some cancers, potentially by enhancing oncogene transcription. In Huntington’s disease, SUPT4H1 depletion ameliorates mutant huntingtin toxicity, highlighting its role in pathogenic RNA metabolism.
Recombinant SUPT4H1 protein is typically produced in *E. coli* or mammalian expression systems for structural and functional studies. Its applications include *in vitro* transcription assays, protein interaction mapping (e.g., with Pol II or SUPT5H), and inhibitor screening for therapeutic development. Structural studies using recombinant SUPT4H1. often combined with cryo-EM, have elucidated its role in the DSIF-Pol II-NELF (Negative Elongation Factor) regulatory axis. Recent efforts target SUPT4H1/SUPT5H complexes with small molecules to disrupt oncogenic transcription, showcasing its potential as a therapeutic target. Research continues to explore its epigenetic roles and tissue-specific regulatory mechanisms.
×
